Salignostics: Pioneering Accessible, Saliva-Based Diagnostics for Global Healthcare

Our Vision

Salignostics is leading the future of diagnostics, delivering accessible, rapid, and reliable saliva-based solutions for global healthcare providers, home-testing markets, and laboratories. Our advanced technology makes testing faster, safer, and more cost-effective than ever.

Challenges in Traditional Diagnostics
Traditional diagnostic methods depend on invasive blood, serum, and urine samples, driving up costs and slowing down operations. These methods often require professional handling and lab resources, creating barriers to fast, accessible healthcare.
Innovative Saliva-Based Diagnostics
With Salignostics’ innovative saliva-based platform, diagnostics become faster, safer, and more scalable. Our easy-to-use solutions reduce the burden on professionals and allow healthcare systems to extend diagnostics to a broader population.

Cutting-Edge Platform Technology

Salignostics’ innovative platform overcomes the challenges of saliva-based testing. By amplifying biomarkers, neutralizing blocking agents, and standardizing sample volumes, we ensure reliable diagnostics that are easy to deploy across multiple environments.
Addressing Key Challenges of Saliva-based Testing:
  • Low Biomarker Concentrations: Our saliva concentrator technology amplifies biomarkers for accurate detection.
  • Inhibitory Agents: We use advanced unmasking capabilities to filter out substances that block visibility.
  • Consistency in Volume and Composition: Our metered collection system standardizes saliva volume for reliable testing.
supported by

Comprehensive Saliva-Based Diagnostics

Collect
Our user-friendly saliva collection method is effective for self-testing at home, point-of-care settings, and for laboratories.
Detect & Test
Our platform can identify a wide range of biomarkers, including human proteins, viral proteins, DNA, and RNA, even those previously undetectable.

The Salignostics Advantage

Accessible
Deploy our universal devices across home and clinical settings, making diagnostics more accessible
Ease of Use
Painless and non-invasive—ideal for children and sensitive populations, ensuring higher compliance
Speed
Get results in minutes, improving the efficiency of healthcare operations and enabling timely intervention
Safety
Non-infective, bio-safe testing minimizes the risk of contamination
Cost-Effective
Reduce overhead costs by eliminating the need for specialized staff and lab infrastructure
Salistick™: A Breakthrough in Pregnancy Testing
Pioneering a new frontier in home diagnostics, Salistick™is the only CE-approved, saliva-based pregnancy test on the market. Available in 1,500+ stores, it has been celebrated as a 2023 Time Magazine Best Invention for its high accuracy, non-invasive approach, and potential for global expansion.

Expanding the Future of Diagnostics

As the demand for accessible, rapid diagnostics grows, Salignostics is leading the charge in the multi-billion-dollar saliva-based diagnostics industry. Our platform addresses critical market gaps, particularly in the fast-growing home diagnostics market, projected to reach $10 billion by 2032.

Meet the Experts Behind Salignostics

At the core of Salignostics’ success is a team of globally recognized experts in saliva diagnostics, biomedical engineering, and healthcare innovation. With over 50 years of combined research experience and 20 years of building successful partnerships, our leadership drives groundbreaking innovations in the field of diagnostics.

Our team has published 50+ peer-reviewed articles, won 15 international awards, and secured 8 prestigious grants from the Israel Innovation Authority. In 2024, we were recognized as one of Time magazine’s 100 Most Influential in Healthcare and were the only saliva diagnostics company to reach the final stage of NIH’s RADx Initiative for COVID-19.

Guy Krief (PhD)
Co-Founder, Deputy CEO
Prof. Aaron Palmon
Co-Founder, President
VP R&D, Hebrew University
Omer Deutsch (DMD, PhD)
Co-Founder, CEO
Raluca Cohen (PhD)
Co-Founder, CSO
Hagai Dror
Chief Strategy & BD
Yoav Neumann (PhD)
Co-Founder, CFO

Our Partners

X